Germline BRCA1 or BRCA2 pathogenic variant in HER2-negative breast cancer (HR+ or TNBC)....
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-BREAST-BRCA-GERMLINE-ACTIONABLE |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-BREAST |
| Sources | SRC-EMBRACA-LITTON-2018 SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 SRC-OLYMPIAD-ROBSON-2017 |
Red Flag Origin
| Definition | Germline BRCA1 or BRCA2 pathogenic variant in HER2-negative breast cancer (HR+ or TNBC). Olaparib (OlympiAD — mPFS 7.0 vs 4.2 mo vs chemo) and talazoparib (EMBRACA — mPFS 8.6 vs 5.6 mo) are FDA-approved for metastatic gBRCA HER2-negative breast. Adjuvant olaparib (OlympiA) for high-risk HER2-negative gBRCA early breast. |
|---|---|
| Clinical direction | intensify |
| Category | high-risk-biology |
| Shifts algorithm | ALGO-BREAST-HR-POS-2L, ALGO-BREAST-TNBC-2L |
Trigger Logic
{
"any_of": [
{
"finding": "brca1_germline",
"value": "pathogenic"
},
{
"finding": "brca2_germline",
"value": "pathogenic"
},
{
"finding": "brca1_brca2_germline",
"value": "positive"
},
{
"finding": "brca1_brca2_pathogenic",
"value": true
},
{
"finding": "germline_brca_status",
"value": "pathogenic"
}
],
"type": "biomarker"
}
Notes
Germline-only — somatic BRCA1/2 in breast lacks the same prospective RCT evidence (use HRD assay where pathway-altered status sought). Genetic counseling mandatory (cascade testing of first-degree relatives; risk-reducing salpingo-oophorectomy). PALB2 has analogous HRR-deficient biology — emerging data support PARPi but off-label. Toxicity: cytopenias (~grade 3 anemia 16-25%), MDS / AML <1.5% long-term. Test before starting any PARPi candidate (chemotherapy de-escalation argument: avoid platinum-based sensitizing regimens if PARPi readily available).
Used By
Algorithms
ALGO-BREAST-HR-POS-2L- ALGO-BREAST-HR-POS-2LALGO-BREAST-TNBC-2L- ALGO-BREAST-TNBC-2L
Red flag
RF-PAN-PALB2-PARPI-CANDIDATE- Germline PALB2 pathogenic variant — BRCA2's recruitment partner; biallelic LOF produces a...